BIOMAT Database Logo BIOMAT Database Logo

Repeated high-dose-melphalan with autologous bone marrow transplantation in acute non lymphocytic leukemia. 1985

B Mascret, and D Maraninchi, and J A Gastaut, and J Camerlo, and G Novakovitch, and H Perrimond, and G Sebahoun, and G Lepeu, and F Rossi, and Y Carcassonne

UI MeSH Term Description Entries
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D008297 Male Males
D008558 Melphalan An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen. Medphalan,Merphalan,Phenylalanine Mustard,Sarcolysine,Sarkolysin,4-(Bis(2-chloroethyl)amino)phenylalanine,Alkeran,L-PAM,Mustard, Phenylalanine
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001853 Bone Marrow The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells. Marrow,Red Marrow,Yellow Marrow,Marrow, Bone,Marrow, Red,Marrow, Yellow
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D003114 Colony-Forming Units Assay A cytologic technique for measuring the functional capacity of stem cells by assaying their activity. Clonogenic Cell Assay,Stem Cell Assay,Clonogenic Cell Assays,Colony Forming Units Assays,Colony-Forming Units Assays,Stem Cell Assays,Assay, Clonogenic Cell,Assay, Colony-Forming Units,Assay, Stem Cell,Assays, Clonogenic Cell,Assays, Colony-Forming Units,Assays, Stem Cell,Colony Forming Units Assay
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration

Related Publications

B Mascret, and D Maraninchi, and J A Gastaut, and J Camerlo, and G Novakovitch, and H Perrimond, and G Sebahoun, and G Lepeu, and F Rossi, and Y Carcassonne
Autologous bone marrow transplantation in acute non lymphocytic leukemia.
November 1985, Revue francaise de transfusion et immuno-hematologie,
B Mascret, and D Maraninchi, and J A Gastaut, and J Camerlo, and G Novakovitch, and H Perrimond, and G Sebahoun, and G Lepeu, and F Rossi, and Y Carcassonne
Repeated courses of high dose melphalan and unpurged autologous bone marrow transplantation in children with acute non-lymphoblastic leukemia in first complete remission.
March 1988, Bone marrow transplantation,
B Mascret, and D Maraninchi, and J A Gastaut, and J Camerlo, and G Novakovitch, and H Perrimond, and G Sebahoun, and G Lepeu, and F Rossi, and Y Carcassonne
High-dose melphalan with autologous bone marrow transplantation for multiple myeloma.
May 1986, Blood,
B Mascret, and D Maraninchi, and J A Gastaut, and J Camerlo, and G Novakovitch, and H Perrimond, and G Sebahoun, and G Lepeu, and F Rossi, and Y Carcassonne
Autologous bone marrow transplantation in acute lymphocytic leukemia (ALL).
January 1992, Leukemia,
B Mascret, and D Maraninchi, and J A Gastaut, and J Camerlo, and G Novakovitch, and H Perrimond, and G Sebahoun, and G Lepeu, and F Rossi, and Y Carcassonne
High dose melphalan and autologous bone marrow transplantation in high risk myeloma.
December 1987, British journal of haematology,
B Mascret, and D Maraninchi, and J A Gastaut, and J Camerlo, and G Novakovitch, and H Perrimond, and G Sebahoun, and G Lepeu, and F Rossi, and Y Carcassonne
Repeated high-dose cyclophosphamide, BCNU and VP-16-213 and autologous bone marrow transplantation in adult acute lymphocytic leukemia in first remission.
May 1984, European journal of cancer & clinical oncology,
B Mascret, and D Maraninchi, and J A Gastaut, and J Camerlo, and G Novakovitch, and H Perrimond, and G Sebahoun, and G Lepeu, and F Rossi, and Y Carcassonne
High-dose busulfan and melphalan before bone marrow transplantation for acute nonlymphoblastic leukemia.
August 1995, Bone marrow transplantation,
B Mascret, and D Maraninchi, and J A Gastaut, and J Camerlo, and G Novakovitch, and H Perrimond, and G Sebahoun, and G Lepeu, and F Rossi, and Y Carcassonne
High-dose chemotherapy and autologous bone marrow transplantation in acute myeloid leukemia.
August 1990, Blood,
B Mascret, and D Maraninchi, and J A Gastaut, and J Camerlo, and G Novakovitch, and H Perrimond, and G Sebahoun, and G Lepeu, and F Rossi, and Y Carcassonne
High-dose AMSA and autologous bone marrow transplantation in relapsed acute leukemia.
November 1982, Cancer treatment reports,
B Mascret, and D Maraninchi, and J A Gastaut, and J Camerlo, and G Novakovitch, and H Perrimond, and G Sebahoun, and G Lepeu, and F Rossi, and Y Carcassonne
Treatment of advanced neuroblastoma with high-dose melphalan and autologous bone marrow transplantation.
January 1986, Cancer chemotherapy and pharmacology,
Copied contents to your clipboard!